Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial-Reference-Cited by-同舟云学术

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Published:2014-10 Issue:11 Volume:15 Page:1269-1278
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

von Minckwitz Gunter,Puglisi Fabio,Cortes Javier,Vrdoljak Eduard,Marschner Norbert,Zielinski Christoph,Villanueva Cristian,Romieu Gilles,Lang István,Ciruelos Eva,De Laurentiis Michele,Veyret Corinne,de Ducla Sabine,Freudensprung Ulrich,Srock Stefanie,Gligorov Joseph

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

2. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010

3. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011

4. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

5. VEGF inhibition: insights from preclinical and clinical studies;Crawford;Cell Tissue Res,2009

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen receptor: Structure, signaling, function and potential drug discovery biomarker in different breast cancer subtypes;Life Sciences;2024-07

2. Pharmaceutical company payments to Japanese breast cancer practice guideline authors;Clinical and Translational Discovery;2024-06

3. Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis;Oncology;2024

4. Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review;The Breast Journal;2024-01

5. Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis;Frontiers in Pharmacology;2023-01-30